News

PharmExec2h
Knipper Health Announces Willis Chandler As new CEO
Willis Chandler is the new president and CEO of Knipper Health. The news came alongside the announcement that Frazier ...
PharmExec7h
FDA Approves Bayer’s Kerendia for Heart Failure with Preserved Ejection Fraction to Reduce Cardiovascular Death and Hospitalization Risk
Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...
PharmExec9h
Strategies in Today’s Market for Pricing and Reimbursement Models
A panel of key opinion leaders consider how payers and manufacturers are increasingly embracing innovative contracting models ...
PharmExec10h
FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir in HIV
The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...
PharmExec13h
New Survey Says Majority of Americans Worry Medicare Won’t Be Around When They Need It
The majority of respondents not already enrolled in the program have concerns that the program won’t survive until the point ...
PharmExec13h
Beyond Approval: Why Your Oncology Label Determines Commercial Success
The specific parameters defined in your label, including patient population, line of therapy, and outcomes measured, will now ...
PharmExec13h
Merck Animal Health’s Bravecto Quantum (Fluralaner for Extended-Release Injectable Suspension) Receives FDA Approval
Bravecto Quantum is the first FDA-approved drug that treats and prevents flea and tick infestations on dogs for a duration of ...
PharmExec13h
Sex-dependent Gene Varient has Positive Outlooks for Men and Negative for Women
rs6190 helps men build muscle mass and reduce diabetes risk, but increases cholesterol levels and elevates the risk of ...